Nemorubicin manufacturers
- Nemorubicin
-
- $51.00
-
2026-07-15
- CAS:108852-90-0
- Purity: 97.79%
- Supply Ability: 10g
- Nemorubicin
-
- $15.00
-
2021-07-13
- CAS:108852-90-0
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Nemorubicin
-
- $15.00
-
2021-07-09
- CAS:108852-90-0
- Min. Order: 1KG
- Purity: 99%+ HPLC
|
| | Nemorubicin Basic information |
| Product Name: | Nemorubicin | | Synonyms: | Nemorubicin;5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-2,3,6-trideoxy-3-(2S)-2-methoxy-4-morpholinyl-.alpha.-L-lyxo-hexopyranosyloxy-, (8S,10S)-;methoxy-morpholynil-doxorubicin;NeMorubincine;PNU152243A; PNU-152243A; PNU 152243A; NEMORUBICIN; METHOXYMORPHOLINYL-DOXORUBICIN;(1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 2,3,6-trideoxy-3-[(S)-2-methoxymorpholino]-alpha-L-lyxo-hexopyranoside;DMM Dox;FCE 23762 | | CAS: | 108852-90-0 | | MF: | C32H37NO13 | | MW: | 643.64 | | EINECS: | | | Product Categories: | ≧99% | | Mol File: | 108852-90-0.mol |  |
| | Nemorubicin Chemical Properties |
| Boiling point | 852.2±65.0 °C(Predicted) | | density | 1.55±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:60.0(Max Conc. mg/mL);101.0(Max Conc. mM) | | pka | 7.35±0.60(Predicted) | | form | Powder | | color | Orange to reddish brown | | InChIKey | CTMCWCONSULRHO-UZGLGGDGNA-N | | SMILES | C12C[C@@](C[C@]([H])(O[C@@H]3O[C@H]([C@@H](O)[C@@H](N4CCO[C@H](OC)C4)C3)C)C=1C(O)=C1C(=O)C3=C(OC)C=CC=C3C(=O)C1=C2O)(O)C(=O)CO |&1:2,4,7,9,10,12,17,r| |
| | Nemorubicin Usage And Synthesis |
| Uses | Nemorubicin is a doxorubicin derivative that differs significantly from its parent drug in terms of spectrum of antitumor activity, metabolism and toxicity profile. The drug is active on tumors resistant to alkylating agents, topoisomerase II inhibitors and platinum derivatives. It works primarily through topoisomerase I inhibition. Of note, Nemorubicin is active in cells with upregulation of the nucleotide excision repair (NER) pathway, where current therapies fail. Nemorubicin is biotransformed in the liver into cytotoxic metabolites that may further contribute to render this drug highly active against primary liver tumors or liver metastases. | | Definition | ChEBI: Nemorubicin is a member of morpholines, an anthracycline antibiotic, a primary alpha-hydroxy ketone and a tertiary alpha-hydroxy ketone. It is functionally related to a doxorubicin. | | in vivo | Nemorubicin is converted to PNU-159682 by human liver cytochrome P450 (CYP) 3A4 in rat, mouse, and dog liver microsomes[2].
Nemorubicin (60 μg/kg) induces sifnificant tumor growth delay in scid mice bearing 9L/3A4 tumors, but shows no obvious effect on the tumor growth delay of 9L tumors in mice by i.v. or intratumoral injection (i.t.). Nemorubicin (40 μg/kg, i.p.) exhibits no antitumor activity and no host toxicity in mice bearing 9L/3A4 tumors[4]. | | target | cancer |
| | Nemorubicin Preparation Products And Raw materials |
|